Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
Thématique(s) / pathologie(s)
- Maladie de Parkinson
Objectifs
Plus d'informations disponibles sur : https://clinicaltrials.gov/ct2/show/NCT02274766?term=Adamas&cond=parkinson&cntry=FR&draw=2&rank=1
Promoteur
Adamas Pharmaceuticals, Inc.
Publication(s) scientifique(s)
-
Oertel W et al. Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3). Mov Disord. 2017 Dec;32(12):1701-1709.
Statut
Résultats publiés